ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer

ARID1A deletion mutation contributes to improved treatment of several malignancies with immune checkpoint inhibitors (ICIs). However, its role in modulating of tumor immune microenvironment (TIME) of gastric cancer (GC) remains unclear. Here, we report an increase of CD8+ T cells infiltration in GC...

Full description

Saved in:
Bibliographic Details
Main Authors: Fangqi Ma, Mingming Ren, Zhongqiu Li, Yujing Tang, Xiaoyu Sun, Yi Wang, Nida Cao, Xiaohong Zhu, Yan Xu, Rui Wang, Yumiao Shen, Ruohan Zhao, Zhaoyan Li, Milad Ashrafizadeh, Gautam Sethi, Furong Wang, Aiguang Zhao
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Pharmacological Research
Subjects:
ARID1A
CD8+ T effector
STAT5
Gastric cancer
Chromatin remodeling
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661824004444
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items